Category Archives: Prevention

Interventions to reduce alcohol use and HIV risk among sexual and gender minority populations: A systematic review

2023

PURPOSE OF REVIEW: Sexual and gender minority (SGM) individuals are diagnosed with HIV at disproportionate rates, and hazardous alcohol use can increase their HIV risk. This review assessed the state...

Non-pharmacological interventions for the prevention of sexually transmitted infections (STIs) in older adults: A systematic review

2023

BACKGROUND: STIs in older adults (adults aged 50 years and older) are on the rise due to variable levels of sex literacy and misperceived susceptibility to infections, among other factors....

Counselling behavioural interventions for HIV, STI and viral hepatitis among key populations: A systematic review of effectiveness, values and preferences, and cost studies

2023

INTRODUCTION: Key populations (sex workers, men who have sex with men, people who inject drugs, people in prisons and other closed settings, and trans and gender diverse individuals) are disproportionately...

Assessing PrEP messaging and communication: A review of the qualitative literature

2023

Pre-exposure prophylaxis (PrEP) is a biomedical HIV prevention intervention approved by the FDA in 2012. Nevertheless, most sexual minority men (SMM) who could benefit from its use are not currently...

HIV prevention intervention-related research with adult, sexual minority hispanic men in the United States: A systematic review

2023

The systematic review describes aims to synthesize the HIV prevention intervention-related research conducted among adult, US sexual minority Hispanic men since 2012. Following PRISMA guidelines, 15 articles representing 14 studies...

Serological response following COVID-19 vaccines in patients living with HIV: A dose-response meta-analysis

2023

To quantify the pooled rate and risk ratio of seroconversion following the uncomplete, complete, or booster dose of COVID-19 vaccines in patients living with HIV. PubMed, Embase and Cochrane library...

Barriers and facilitators to HIV pre-exposure prophylaxis for cisgender and transgender women in the UK

2023

Uptake of oral HIV pre-exposure prophylaxis (PrEP) among cisgender and transgender women in the UK has been low. In this Review, we explore the barriers and facilitators to PrEP access...

Undetectable=Untransmittable=Universal Access (U=U=U): Transforming a foundational, community-led HIV/AIDS health informational advocacy campaign into a global HIV/AIDS health equity strategy and policy priority

2023

BACKGROUND: Undetectable=Untransmittable (U=U) first emerged in 2016 as a health information campaign to promote rigorous scientific evidence that people living with HIV (PLHIV) on effective treatment who have reached an...

Can peer-based interventions improve adolescent sexual and reproductive health outcomes? An overview of reviews

2023

PURPOSE: An overview of reviews was conducted to summarize the evidence and synthesize the results from systematic reviews. METHODS: The Cochrane and Preferred Reporting Items for Overviews of Reviews reporting...

HIV focused sexual risk-reduction interventions targeting adolescent boys and young men in sub-Saharan Africa: A scoping review

2023

Adolescent girls and young women’s exceptionalism with HIV interventions has left adolescent boys and young men (ABYM) trailing behind, thus becoming a marginalized and underserved population. The scoping review aimed...

Implementation and resource needs for long-acting PrEP in low- and middle-income countries: A scoping review

2023

INTRODUCTION: Several low- and middle-income countries (LMICs) are preparing to introduce long-acting pre-exposure prophylaxis (LAP). Amid multiple pre-exposure prophylaxis (PrEP) options and constrained funding, decision-makers could benefit from systematic implementation...

Systematic review of the values and preferences regarding the use of injectable pre-exposure prophylaxis to prevent HIV acquisition

2023

INTRODUCTION: Pre-exposure prophylaxis (PrEP) is an important HIV prevention option. Two randomized trials have provided efficacy evidence for long-acting injectable cabotegravir (CAB-LA) as PrEP. In considering CAB-LA as an additional...

Email 1 selected articles

Email 1 selected articles

Error! The email wasn't sent. Please try again.

Your email has been sent!